evipedia.ai
← Back

Microdosing LSD Analogues for Health & Longevity

Evidence Review created on 08/05/2026 using AI4L / Opus 5

Also known as: 1P-LSD, 1cP-LSD, 1V-LSD, 1B-LSD, 1D-LSD, ALD-52, AL-LAD, ETH-LAD, LSZ, MIPLA, Lysergamide Prodrugs, Legal LSD Analogues

Motivation

LSD (lysergic acid diethylamide) analogues are laboratory-made cousins of LSD — compounds such as 1P-LSD, 1cP-LSD and 1V-LSD — that carry a small chemical add-on which the body strips away, releasing LSD itself. Microdosing means taking roughly a tenth of a recreational amount, too small to produce a psychedelic experience, every few days. Because the add-on changes the molecule’s legal identity, these analogues have become the most widely circulated material for the practice.

The practice spread through online communities during the 2010s, and dozens of these analogues have since turned up on blotter paper in Europe, Japan and North America, often faster than laws can name them. Interest among people focused on healthy ageing centres on claims of steadier mood and better sleep, alongside laboratory signals that serotonin-targeting compounds may quiet inflammation in the brain.

This review examines what is actually known about microdosing LSD analogues: how the compounds behave in the body, what controlled human trials of low-dose LSD have measured, what the practice may cost in terms of heart, mind and legal exposure, and where the evidence is thin, contested, or absent altogether.

Benefits - Risks - Protocol - Conclusion

A curated set of high-level resources that frame what LSD analogues are chemically and what controlled research on low-dose LSD has and has not shown.

  • Microdosing Psychedelics: Current Evidence From Controlled Studies - Murphy et al., 2024

    A compact narrative synthesis of the 14 laboratory studies that used investigator-supplied drug and double-blind procedures, all of which involved 5–20 µg of LSD. It is the cleanest available separation of what controlled dosing actually produces from what the practice is popularly credited with.

  • Pharmacological and biotransformation studies of 1-acyl-substituted derivatives of d-lysergic acid diethylamide (LSD) - Halberstadt et al., 2020

    The foundational experimental demonstration that ALD-52, 1P-LSD and 1B-LSD are prodrugs — compounds that are inactive until the body converts them — rather than distinct drugs in their own right. It is the single most load-bearing paper for anyone deciding whether LSD data transfer to the analogues.

  • Dr. Robin Carhart-Harris: The Science of Psychedelics for Mental Health - Andrew Huberman

    A long-form conversation with one of the field’s principal investigators that explicitly contrasts microdosing with full-dose sessions and works through how placebo control is handled in psychedelic trials. Useful for calibrating expectations before reading primary studies.

  • #182 – David Nutt: Psychedelics & Recreational Drugs - Peter Attia

    A structured walk through the pharmacology, addiction potential and comparative harm ranking of psychedelics against other controlled substances, from a researcher who has led national drug-harm assessments. It provides the regulatory and risk-proportionality context that purely clinical papers omit.

  • Biohacking Your Ancestral Lifestyle, with Ben Greenfield - Chris Kresser

    The one piece of expert-platform content that addresses the analogues rather than LSD, with a segment describing 1P-LSD by name, the 10–20 µg range used in practice, and the gray-market sourcing and legal ambiguity that come with it. It is a useful record of how the practice is framed inside the health-optimisation community, and of the claims that the controlled literature has since tested.

Note on priority experts: Of the prioritised sources, Huberman Lab, Peter Attia and Chris Kresser carry topic-relevant material and are all represented above. Direct searches of foundmyfitness.com returned only tag pages and short study summaries touching LSD within broader psychedelic coverage rather than a dedicated article or episode; lifeextension.com mentions LSD only inside its broader depression and anxiety protocols, as one entry in a list of full-dose psychedelic therapies, with nothing on microdosing or on the lysergamide analogues. The list has therefore been completed with primary and narrative academic sources rather than padded with marginally relevant material.

Grokipedia

  • 1P-LSD

    The primary dedicated entry for the archetypal LSD analogue, covering its chemistry as 1-propionyl-d-lysergic acid diethylamide, its prodrug relationship to LSD, and its shifting legal status across jurisdictions. Grokipedia also maintains separate entries for 1cP-LSD, 1V-LSD, 1B-LSD and 1D-LSD, which together map the full analogue family.

Examine

  • LSD

    Examine’s dedicated intervention page for the parent compound, summarising the evidence for psychiatric applications; because the 1-acyl analogues are prodrugs that release LSD, this is the applicable entry. No page exists for 1P-LSD, 1cP-LSD or any other analogue, so the analogue-specific chemistry and purity issues covered in this review are not addressed there.

ConsumerLab

No ConsumerLab article exists for LSD analogues, for LSD, or for microdosing. ConsumerLab’s testing programme is restricted to dietary supplements and consumer health products sold through legitimate retail channels, and it does not evaluate controlled substances or unscheduled research chemicals distributed through gray markets.

Systematic Reviews

Systematic reviews and meta-analyses covering low-dose psychedelic use, all of which pool LSD data that carry over to its prodrug analogues.

Mechanism of Action

The 1-acyl LSD analogues — ALD-52, 1P-LSD, 1B-LSD, 1cP-LSD, 1V-LSD and 1D-LSD — are best understood not as separate drugs but as delivery vehicles for LSD. Each carries an acyl group (a small carbon-based chemical attachment) on the indole nitrogen at position 1 of the lysergamide skeleton. That attachment sharply reduces the molecule’s own receptor activity, and it is removed in the body to release LSD.

Historical Context & Evolution

  • Original intended use. LSD was synthesised in 1938 and its psychoactivity discovered in 1943. Through the 1950s and 1960s it was distributed to researchers and clinicians as an investigational psychiatric agent, and full doses were studied for pain in terminally ill patients — work that reported profound analgesia and was abandoned not because it failed but because the compound was scheduled worldwide. ALD-52 (1-acetyl-LSD) dates from this same era and was characterised as roughly equipotent with LSD in humans.

  • The analogues were created to occupy legal space, not therapeutic space. Unlike ALD-52, compounds such as 1P-LSD, 1B-LSD, 1cP-LSD, 1V-LSD and 1D-LSD did not exist before their appearance as research chemicals. Each was introduced after its predecessor was named in legislation, producing a documented sequence: 1P-LSD from around 2015, 1cP-LSD from 2019, 1V-LSD after Germany’s controlled-substances update in 2021, and 1D-LSD after 1V-LSD was in turn scheduled. Forensic laboratories continue to identify further variants in seized blotter, including 1cP-AL-LAD, 1cP-MIPLA and LSZ, of which the first two have had no metabolic pathway or biological activity reported at all.

  • How the compounds came to be considered for health optimisation. Microdosing as a named practice was popularised through online communities in the mid-2010s, framed around productivity, mood and creativity rather than disease treatment. Because illicitly produced LSD is controlled and of unverified potency, and because analogues were sold on quantified blotter through open web vendors, the analogues rapidly became the default supply for the practice. The longevity framing arrived later, borrowing the anti-inflammatory and neuroplasticity rationales developed for full-dose psychedelic research.

  • What the early findings actually showed, and how they were received. The pre-prohibition literature is frequently written off as uncontrolled. A systematic recovery of 44 studies spanning 1955 to 2021 found that the older laboratory work did document reproducible changes in pain perception, time perception and neurophysiology — findings that are consistent in direction with modern controlled work on pain and sleep, and that were not refuted so much as interrupted. The historical claim that low doses reliably enhance creativity, by contrast, has not survived controlled testing.

  • Evolution of scientific opinion is still in motion. The dominant current reading is that microdosing benefits are largely expectancy effects. That reading rests heavily on one self-blinding citizen-science dataset and on null repeated-dosing trials in healthy volunteers, and its own authors note that participants broke blind. Against it sit objectively measured, placebo-controlled effects on sleep duration and a large home-administration trial showing credible on-dose subjective improvement. The reasonable position is not that the question has been settled in either direction but that the effect, if real, is small, acute and easily swamped by expectation — and that no trial has ever tested the analogues themselves.

Expected Benefits

Benefits below are graded on the strength of the underlying evidence; for every health outcome listed, that evidence is human. A structural caveat applies to every item: no clinical trial has ever been conducted on an LSD analogue. All human data derive from LSD itself, and transfer to the analogues rests on the prodrug relationship, which is established across in vitro, animal and human-serum work rather than by direct testing of the analogues in people.

Medium 🟩 🟩

Predictable, LSD-Equivalent Pharmacology at a Stated Dose

The practical benefit that drives adoption is not a health outcome but dose control. Illicit LSD blotter is of unverifiable potency, whereas analogue blotter is typically produced to a stated microgram loading, and the prodrug relationship means the resulting exposure is LSD exposure. The evidence for that relationship converges from several independent directions: 1-acyl substitution cripples direct receptor activity, yet high plasma LSD appears in rats after ALD-52 and 1P-LSD dosing and human serum converts 1cP-LSD to LSD in vitro, behavioural potency in animals tracks closely across the family, and ALD-52 was characterised in humans decades ago as roughly equipotent with LSD. The grade is held to Medium rather than High because none of that is a modern human trial of any analogue, and convergence across in vitro, rodent and historical data cannot substitute for one. The limitation that follows is that conversion efficiency has never been measured in humans, so the microgram figure on a blotter is a nominal rather than a delivered dose.

Magnitude: Mouse head-twitch potency is closely clustered across analogues — 1P-LSD at an ED50 of 349.6 nmol/kg and 1cP-LSD at 430.0 nmol/kg — and 1-acyl substitution lowers direct 5-HT2A affinity by one to two orders of magnitude while leaving in vivo potency largely intact.

Increased Sleep Duration the Night After Dosing

The single most robust objective finding in the entire microdosing literature. In a placebo-controlled trial, healthy men taking 10 µg of LSD every third day for six weeks wore commercial sleep trackers throughout, and slept measurably longer on the night following each dose, with no reduction in sleep on the dosing day itself. The proposed mechanism is a genuine shift in physiological sleep requirement rather than sedation, since the proportions of time spent in each sleep stage and daytime physical activity were unchanged. Because the endpoint was device-measured rather than self-reported, it is difficult to attribute to expectation. It remains a single trial in one sex, and its authors disclose research funding from MindBio Therapeutics Ltd., the company commercialising a titratable LSD microdose formulation — a direct financial interest that applies to this whole University of Auckland programme, which also produced the mood and depression findings below.

Magnitude: 24.3 additional minutes of sleep per post-dose night (95% CI, confidence interval — the range within which the true value most likely falls — 10.3 to 38.3 minutes), across 3,231 nights of recording in 80 participants.

Acute Mood Elevation and Subjective Well-Being on Dosing Days ⚠️ Conflicted

The benefit most people are seeking, and the one the evidence handles least consistently. In the largest home-administration trial, daily questionnaires showed credible evidence at above 99% posterior probability (the statistical confidence, after weighing the data, that the effect is real) of improved creativity, connectedness, energy, happiness, irritability and wellness on dose days compared with non-dose days, and these held after controlling for pre-intervention expectancy. Laboratory work agrees that effects are perceptible and dose-ordered, with 10 µg raising ratings of “good drug effect” and 20 µg raising both good and bad effects. Against this, four repeated doses of 13 or 26 µg under laboratory conditions did not improve mood at all, and the self-blinding citizen study found the placebo arm improved just as much. The conflict tracks setting and endpoint rather than substance: the positive findings come from daily on-dose questionnaires during naturalistic home dosing, where participants can tell dose days apart, while the null findings come from supervised laboratory sessions scored on pre-post batteries that only register change persisting beyond the dosing day — so a transient on-dose lift, inflated to an unknown degree by expectation, would produce exactly this pattern.

Magnitude: Improvements confined to dosing days with no change between baseline and six-week endpoint on any questionnaire; the threshold dose for any detectable psychotropic effect is 10 µg of LSD base.

Favourable Short-Term Tolerability in Older Adults

Directly relevant to a longevity-oriented reader, since almost all other trials recruit young adults. A phase 1 study gave 5, 10 or 20 µg or placebo on six occasions at four-day intervals to 48 healthy volunteers with a mean age of 62.9 years, and found adverse events no more frequent than with placebo and no impairment of cognition, balance or proprioception. Balance and proprioception (the body’s sense of its own position) matter disproportionately in this age group because falls are a major driver of late-life decline. The trial was designed and funded by Eleusis Benefit Corporation, a company developing LSD as a medicine, and its authors were company employees — a direct financial interest in a favourable tolerability result.

Magnitude: Adverse event frequency no higher than placebo across 21 days of repeated dosing in 48 adults averaging 62.9 years; plasma LSD was undetectable at 5 µg, with peak levels at 30 minutes for the 10 and 20 µg groups.

Low 🟩

Acute Increase in Circulating Neuroplasticity Signalling

The only direct human evidence that low-dose LSD engages a growth-factor pathway. In a placebo-controlled within-subject study, single doses of 5, 10 and 20 µg raised BDNF blood plasma levels at four hours (5 µg) and six hours (5 and 20 µg) relative to placebo. The proposed mechanism is 5-HT2A-linked stimulation of synaptic remodelling. The evidence basis is a single small crossover study measuring a blood marker, not brain tissue; the dose-response was not orderly, which is unusual for a genuine pharmacological effect; and no study has linked microdose-induced BDNF changes to any cognitive or structural outcome.

Magnitude: Statistically significant plasma elevations at 4 and 6 hours post-dose in a single crossover study; no effect size for downstream cognitive or structural change has been established.

Reduction in Depressive Symptoms

An eight-week open-label trial in 19 adults with major depressive disorder (a clinical depression diagnosis requiring persistent low mood and loss of interest) used 16 doses of LSD, starting at 8 µg and titrated between 6 and 20 µg twice weekly at home. Depression scores fell by 59.5% by the end of the intervention and the improvement was sustained for up to six months, with parallel gains in anxiety, rumination, stress and quality of life. Most participants remained on antidepressant medication throughout. The grade is Low because the design was open-label with no control arm, the sample was small and predominantly male, and open-label psychedelic trials are exceptionally vulnerable to expectation; the same group’s randomised follow-up finished collecting data in September 2025 and has not yet reported.

Magnitude: 59.5% reduction in depression rating-scale scores from baseline in 19 participants, sustained to six months — uncontrolled, so the placebo-attributable share is unknown.

Acute Reduction in Pain Sensitivity ⚠️ Conflicted

Directly contradicted between two trials from overlapping research groups. In the first, 24 healthy volunteers given 5, 10 and 20 µg showed significantly longer cold-water tolerance and lower ratings of pain and unpleasantness at 20 µg. In the second, 15 µg given over four administrations produced no analgesic effect on any measure in the full sample, with only a marginal post-hoc signal in participants who had not hit a ceiling on the pain task. The most plausible reconciliation is a dose threshold sitting between 15 and 20 µg — above the range most microdosing schedules use — compounded by a task that saturates in tolerant individuals.

Magnitude: Significant increase in cold-pressor tolerance at 20 µg; no effect whatsoever at 15 µg, including on subjective pain and unpleasantness ratings.

Speculative 🟨

Reduced Neuroinflammation and Delayed Neurodegeneration

The mechanism most often invoked to justify microdosing as a longevity practice. Preclinical work shows that 5-HT2A signalling suppresses inflammatory cascades, and this rationale was explicit in designing the older-adult tolerability trial as groundwork for Alzheimer’s disease prevention. The basis is entirely mechanistic and preclinical: no human trial of repeated low-dose LSD or of any analogue has measured an inflammatory marker, a neuroimaging biomarker of neurodegeneration, or a cognitive trajectory over a period long enough to matter. Nothing about the practice has been tested against a disease endpoint.

Enhanced Creativity and Cognitive Performance

The most widely claimed benefit and the least supported. Anecdotal reports and survey data are abundant, and the acute questionnaire signal for self-rated creativity is real, but controlled testing has repeatedly failed to reproduce it on objective tasks — and pooled analysis points in the opposite direction, which is treated as a risk in this review rather than a benefit. The basis for this item is anecdotal and self-report only, with no controlled study demonstrating an objective creative or cognitive gain.

Prevention of Cluster Headache and Migraine

The oldest therapeutic claim attached to low-dose lysergamides, and the one furthest from the longevity framing that otherwise drives the practice. Cluster headache (a rare disorder of repeated, extremely severe one-sided head pain occurring in bouts) and migraine have been reported for decades to remit for months after a small number of sub-hallucinogenic doses, and observational data, case reports and a few small controlled trials of sub-hallucinogenic dosing point to benefit in both conditions. The proposed mechanism is 5-HT2A-linked resetting of trigeminal and hypothalamic signalling rather than acute analgesia, which is why the effect is described as preventive rather than dose-linked. This is also the only indication for which an LSD analogue has been developed deliberately: BOL-148 (2-bromo-LSD, a non-hallucinogenic lysergamide) was tested open-label in a handful of cluster headache patients. For the 1-acyl analogues covered here the basis is anecdotal and observational only — no controlled trial of low-dose LSD, and none of any prodrug analogue, has ever used a headache endpoint, and the regimens described in the headache literature are episodic bursts rather than the continuous schedules used for microdosing.

Extension of Healthspan or Lifespan

No study in any species has tested whether repeated low doses of LSD or its analogues affect lifespan, biological-age markers, or any established hallmark of ageing. The basis is inference from serotonergic and neuroplasticity mechanisms that are themselves only loosely connected to ageing biology, and from the general observation that agents affecting inflammation sometimes affect longevity. There is no controlled or observational human data of any kind on this endpoint.

Benefit-Modifying Factors

  • CYP2D6 metabolic status: CYP2D6 is the liver enzyme that performs much of LSD’s breakdown, and roughly 5–10% of people of European ancestry are poor metabolisers while a smaller fraction are ultrarapid. Poor metabolisers have been shown with full-dose LSD to have substantially higher and longer-lasting exposure, meaning a nominal 10 µg microdose may behave like 15–20 µg — pushing a sub-perceptual dose into perceptible territory and altering both benefit and blinding.

  • Baseline serotonergic drug exposure: People already taking a selective serotonin reuptake inhibitor (a common antidepressant class that raises serotonin availability) or who have taken one long-term typically show blunted responses to psychedelics, attributed to receptor downregulation. Because a large share of people seeking mood benefits are already medicated, this is the single most common reason for a null personal result.

  • Baseline mood and symptom burden: The clearest signal to date came from an open-label trial in people with diagnosed depression, where scores fell substantially, whereas repeated-dose trials in healthy volunteers with normal mood found no improvement at all. Ceiling effects mean a well-functioning person has little room to improve on the instruments used, so the expected effect is smaller than in a symptomatic one.

  • Baseline sleep architecture: The sleep-duration finding was obtained in healthy young men with unremarkable sleep. Someone already sleeping at their physiological requirement has less headroom for an extra 24 minutes than someone chronically curtailed, and the benefit is plausibly larger in the sleep-restricted.

  • Sex-based differences: The two largest controlled datasets — the six-week home-administration trial and the sleep analysis — enrolled men only, and systematic reviews of the field repeatedly flag pronounced sex imbalance as a limitation. Whether women respond similarly is unknown; a trial of microdosing in women with premenstrual disorders is the first to address this directly, and hormonal cycling is a plausible modifier given serotonin’s interaction with oestrogen signalling.

  • Age: Tolerability data in adults averaging 62.9 years are reassuring, but that trial measured safety rather than benefit, and no efficacy endpoint has been tested in older adults. Age-related decline in liver enzyme activity and increased sensitivity to blood-pressure changes both argue for treating a given dose as functionally larger in later decades.

  • Pre-existing health conditions: Anxiety disorders substantially change the expected balance, since treatment-emergent anxiety was the leading reason for withdrawal in controlled trials. Pre-existing valvular heart disease removes any acceptable margin for the 5-HT2B concern. Conversely, chronic pain populations were where mid-century work found the strongest low-dose signal, and remain the group with the most plausible untested upside.

  • Expectancy and belief: Uniquely for this intervention, the expectation of benefit is itself a benefit-modifying factor with direct experimental support. Participants who believed they had received the drug improved regardless of what they actually took, which means a person’s prior conviction materially shapes their reported outcome.

Potential Risks & Side Effects

Risks are graded on the strength of the human evidence. Two structural risks apply to the whole category and are graded individually below: no analogue has ever been given to a human under controlled conditions, and the compounds are supplied by unregulated vendors.

High 🟥 🟥 🟥

Treatment-Emergent Anxiety

The most consistently reported adverse effect and the leading cause of trial dropout. In the six-week home-administration trial, treatment-related anxiety was the most notable adverse event and prompted the withdrawal of four participants from the LSD group; the open-label depression trial also lost a participant to dosing-day anxiety. The proposed mechanism is the same 5-HT2A activation that produces the desired effects, with the difference being interpretation and setting rather than pharmacology. The systematic review of harms lists anxiety among the three most common effects across 31 studies. It is dose-dependent, short-lived, and fully reversible on discontinuation — but it occurs in a supervised trial context, which is more favourable than unsupervised home use.

Magnitude: 4 of 40 participants (10%) withdrew from the LSD arm of a six-week controlled trial because of treatment-related anxiety.

Acute Blood Pressure Elevation

Consistently observed across independent laboratories and directly relevant to a longevity-focused reader, for whom cumulative vascular load matters more than any single reading. Placebo-controlled studies report that LSD elevated mean blood pressure at 20 µg and that 15 µg increased blood pressure on administration days, and the dedicated harms review identifies raised blood pressure as one of the three most common adverse effects. The mechanism is narrowing of blood vessels driven by adrenaline and serotonin signalling, a class effect of ergoline compounds (the chemical family that includes LSD and the ergot-derived medicines). Elevations were within the normal range in healthy young volunteers; the concern is the untested case of chronic dosing in someone with existing hypertension.

Magnitude: Dose-dependent rises that remained within the normal range at 5–20 µg in healthy volunteers, but reproducibly present at every dose above the 10 µg perceptual threshold and ranked among the three most frequently reported effects across 31 studies.

Impaired Cognitive Control

The best-quantified harm, and it directly contradicts the practice’s central claim. Pooled analysis of 59 effect sizes from 14 studies and 1,614 participants found a significant decrease in cognitive control with no detectable benefit in any other cognitive domain; an independent umbrella review put the pooled effect at a small but reliable impairment. Cognitive control is the capacity to override automatic responses and hold to an intention — the faculty most relevant to demanding professional work. Neither substance, dose (6.5–20 µg), nor duration (1–42 days) moderated the effect, and it was present whether measured on or off drug. The proposed mechanism is reduced top-down filtering, the same loosening framed positively as cognitive flexibility.

Magnitude: Pooled Cohen’s d (a standardised measure of effect size, where 0.2 is small and 0.8 is large) of −0.34 (95% CI −0.62 to −0.06) for cognitive control — a small effect, unmoderated by substance, dose or duration.

Medium 🟥 🟥

Unknown Compound Identity and Uncharacterised Analogues

A risk specific to this intervention rather than to LSD. Forensic laboratories repeatedly find blotter containing compounds other than those advertised, including 1cP-AL-LAD, 1cP-MIPLA, 1V-LSD and LSZ, of which the first two have had no metabolic pathway or biological activity reported at all. The mechanism of harm is straightforward: a buyer who believes they are taking a well-characterised prodrug may be taking a molecule with different receptor selectivity, different potency, and no toxicological history whatsoever. The evidence basis is blotter seizure analysis by a national forensic institute, reported for products circulating in Japan. Severity ranges from a null result to an unpredictable pharmacological exposure.

Magnitude: Four lysergamides identified in a single national blotter-analysis series, three of them newly distributed and two with no published pharmacology at all; new analogues continue to appear faster than they are characterised.

Chemical Instability and Dose Drift

The acyl group that defines these compounds is also their weak point. ALD-52 hydrolyses to LSD readily, and 1P-LSD does the same though more slowly because its bulkier propanoyl group physically shields the bond, with the degree of conversion more pronounced at lower concentrations — the direction that disadvantages dilute microdose preparations. The evidence basis is forensic analytical chemistry rather than a shelf-life study: the conversion was measured during gas chromatography, where alcoholic extraction solvents and a heated injector port drive the reaction, and no study has tracked prodrug content in stored blotter over time. The inferred consequence is that material exposed to alcohol solvents or heat shifts between prodrug and free LSD, and because conversion in the body is not instantaneous, the onset and effective potency of a dose can change — an extrapolation from the chemistry, not a demonstrated storage effect.

Magnitude: ALD-52 converts substantially faster than 1P-LSD, with hydrolysis more pronounced at 0.1 mg/mL than at higher concentrations — the direction that disadvantages low-dose preparations.

Expectancy-Driven Benefit and Misallocated Effort ⚠️ Conflicted

Not a physiological harm but the most probable practical cost. In the largest placebo-controlled dataset, all psychological outcomes improved from baseline in the microdose group — and the placebo group improved just as much, with no significant between-group differences; the small acute differences that did appear were attributable to participants breaking blind. Against this sit device-measured sleep effects and a large home trial reporting on-dose improvements that survived adjustment for expectancy. The conflict is genuine and unresolved. For a reader allocating finite effort across interventions, the risk is committing months to a practice carrying legal and cardiac uncertainty for an effect that may be reproducible with belief alone.

Magnitude: No significant drug-versus-placebo difference on any psychological outcome across 191 participants in the largest placebo-controlled microdosing dataset.

The analogues exist because of legal arbitrage, and that arbitrage is closing. 1P-LSD is explicitly controlled in the United Kingdom and under Germany’s New Psychoactive Substances Act; 1V-LSD and subsequently 1D-LSD were each brought under German control within a few years of appearing. In the United States most analogues are unscheduled but, because they convert to a Schedule I substance, are prosecutable under the Federal Analogue Act. The consequence is both legal jeopardy and practical instability: a person’s supply may become criminal without notice, forcing an unplanned discontinuation or a switch to a newer, less characterised compound.

Magnitude: At least four successive analogues have been scheduled in sequence in a single jurisdiction since 2015, each within roughly two to three years of market appearance.

Low 🟥

Tolerance to Repeated Dosing

LSD produces rapid tolerance at full doses through 5-HT2A receptor downregulation, which is why the practice universally uses spacing of three to four days rather than daily dosing. Whether meaningful tolerance develops at microdose exposures is untested; controlled trials using three- to four-day intervals for up to six weeks did not report escalating dose requirements. The mechanism is well established at higher exposures, and the evidence basis at microdose level is the absence of reported escalation in short trials rather than direct measurement. Reversal is expected within days of stopping.

Magnitude: No dose escalation reported over 14 doses across six weeks at three-day intervals; tolerance has not been directly measured at microdose exposures.

Sleep-Onset Disruption with Late-Day Dosing

The parent compound is stimulant-like in its acute profile, with peak plasma levels at about one hour and psychotropic effects lasting to roughly five hours after a 10 µg dose. Dosing in the afternoon or evening therefore places active drug in the pre-sleep window. Controlled data are reassuring — no reduction in sleep was observed on dosing days themselves — but those trials dosed in the morning by protocol, so they do not test late dosing. The prodrug step adds a further delay of uncertain length, shifting the effective window later than an equivalent LSD dose would.

Magnitude: Psychotropic effects begin at about 1.1 hours and end at about 5.1 hours after 10 µg; no sleep reduction was seen on dosing days under morning-dosing protocols.

Headache, Nausea and Gastrointestinal Discomfort

Commonly reported in survey and open-label data and consistent with ergoline pharmacology, which affects both vascular tone and gut serotonin signalling. The dedicated harms review characterises the side-effect profile overall as dose-dependent, mild and short-lived, with these somatic complaints appearing below anxiety, blood-pressure elevation and cognitive effects in frequency. Severity is low and resolution occurs within hours. The evidence basis is predominantly self-report rather than systematic adverse-event capture, which is why the grade is not higher.

Magnitude: Reported as mild and short-lived across the 31 studies pooled in the dedicated side-effect review, ranking below anxiety, raised blood pressure and cognitive impairment in frequency.

Speculative 🟨

Valvular Heart Disease from Chronic 5-HT2B Activation

The most serious theoretical risk and the one most relevant to a longevity horizon, because it accrues over years rather than weeks. LSD and its metabolites bind 5-HT2B receptors with potency equal to or greater than at 5-HT2A and act there as partial agonists — the same pharmacology that caused valve disease with fenfluramine, pergolide and methysergide. A dedicated risk assessment — authored by staff of Delos Therapeutics, Delos Psyche Research Group and Verdient Science, commercial psychedelic developers with their own financial interest in how this risk is framed — concluded that safety margins from typical microdose plasma levels are wider than for drugs known to damage heart valves but not reassuring, and that no animal or clinical study designed to evaluate this risk existed. Since then, chronic low-dose LSD in mice produced no ventricular or valvular remodelling on echocardiography, and the first human trial to include echocardiography after repeated dosing found no valvular changes over eight weeks in 19 people. Both are short relative to the exposure that matters, and the mouse work leaves the underlying receptor argument intact rather than refuting it.

Compound-Specific Cardiac and Genotoxic Signals

Computational toxicology profiling of the five common analogues predicted markedly different risk patterns across them, with the strongest cardiac ion-channel inhibition for 1V-LSD, elevated pulmonary risk predictions for 1V-LSD and 1cP-LSD, and genotoxicity alerts (flags for potential DNA damage) for ALD-52 and 1cP-LSD, though a separate platform in the same analysis classified all five as non-mutagenic. The basis is entirely in silico: no wet-laboratory assay, animal study or human observation supports or refutes any of these predictions. Their value is in flagging that the analogues are not interchangeable with each other or with LSD on safety grounds, not in establishing that any specific harm occurs.

Hallucinogen Persisting Perception Disorder

A condition in which visual disturbances such as trails or static persist long after drug exposure has ended. It is documented after full psychedelic doses at low incidence, and isolated case reports exist in people who microdose, but no controlled study has assessed incidence at sub-perceptual doses and no mechanism specific to low exposure has been proposed. The basis is isolated case reporting only.

Precipitation of Hypomania or Mania in Susceptible Individuals

Psychedelics can trigger elevated mood states in people with bipolar-spectrum vulnerability, and this is documented for full doses. Whether repeated sub-perceptual dosing carries the same liability is untested; the pharmacological argument for concern is that the same receptor is engaged repeatedly over weeks rather than once. The basis is extrapolation from full-dose case series and mechanistic reasoning, with no microdose-specific data.

Risk-Modifying Factors

  • CYP2D6 poor-metaboliser status: Reduced activity of this liver enzyme raises and prolongs LSD exposure from any given dose, which shifts the entire risk profile upward — anxiety, blood-pressure elevation and cognitive interference all track exposure. Combined with the nominal-versus-delivered dose uncertainty inherent to prodrugs, this is the single genetic factor most likely to convert an intended microdose into a perceptible one.

  • 5-HT2A receptor variants and serotonin transporter polymorphisms: Variation in the gene encoding the 5-HT2A receptor and in the serotonin transporter promoter region (a stretch of DNA controlling how much serotonin-recycling protein is produced) is associated with differing psychedelic response intensity and with baseline anxiety proneness. Carriers of higher-anxiety genotypes are the plausible subset behind the 10% anxiety-driven withdrawal rate seen in trials.

  • Baseline blood pressure: Every controlled study showing pressure elevation enrolled volunteers with normal blood pressure, so the observed rises stayed inside the normal range by construction. Someone starting at 140/90 mmHg (millimetres of mercury, the standard blood-pressure unit) has no such buffer, and repeated small elevations two to three times weekly over months is an untested cumulative exposure.

  • Baseline echocardiographic findings: Any pre-existing valve abnormality — even trivial regurgitation (a small backward leak of blood through a heart valve that does not close fully) — removes the margin on which the 5-HT2B argument rests, since the concern is progression of fibrotic change rather than its initiation. This is the one baseline measurement whose result categorically changes the risk picture.

  • Sex-based differences: The controlled safety data are overwhelmingly male; the six-week trial and the sleep analysis enrolled men exclusively, and reviews of the field name sex imbalance as a standing limitation. Women additionally carry a higher baseline risk of drug-induced valve disease with serotonergic agents, and the historical fenfluramine valve-disease signal was strongest in women — which makes the least-studied group the one with the more plausible concern.

  • Psychiatric history: A personal or family history of bipolar disorder or psychotic illness converts a speculative risk into a foreseeable one, and existing anxiety disorder predicts the most common adverse effect. Long-term antidepressant use cuts the other way, blunting both effects and side effects.

  • Age: Repeated dosing was well tolerated in adults averaging 62.9 years with no impairment of balance or proprioception, which is the most directly reassuring safety dataset for an older reader. Against this, age brings declining enzyme activity, higher prevalence of subclinical valve disease, more concurrent medication, and greater consequence from any transient blood-pressure rise.

  • Concurrent cardiovascular or serotonergic medication: Existing use of ergot-derived migraine drugs, dopamine agonists or serotonergic agents adds to the same receptor load that underlies the fibrosis concern, and is the situation in which a theoretical risk becomes an additive one.

Key Interactions & Contraindications

  • Selective serotonin reuptake inhibitors and serotonin-noradrenaline reuptake inhibitors (fluoxetine, sertraline, escitalopram, venlafaxine, duloxetine): Severity — caution, with expected loss of effect. Chronic use downregulates 5-HT2A receptors and reliably blunts psychedelic response; the clinical consequence is a null result that invites dose escalation into perceptible and higher-risk territory. Mitigation: recognise the blunting rather than compensating with larger doses, and make no changes to antidepressant therapy for this purpose.

  • Monoamine oxidase inhibitors (phenelzine, tranylcypromine, moclobemide) and the antibiotic linezolid: Severity — absolute contraindication. MAOIs (monoamine oxidase inhibitors, an older antidepressant class that blocks serotonin breakdown) can potentiate serotonergic agents unpredictably, with risk of serotonin syndrome (a dangerous state of agitation, fever, rapid heart rate and muscle rigidity from serotonin excess). Mitigation: avoid entirely; no separation interval is considered adequate given MAOI enzyme-inhibition duration.

  • Lithium: Severity — absolute contraindication. Case reports of seizures and prolonged, severe reactions when lithium is combined with classic psychedelics are among the most consistent serious interaction signals in the field. Mitigation: avoid; the combination has no safe dose-reduction strategy.

  • Tricyclic antidepressants (amitriptyline, imipramine, nortriptyline): Severity — caution. These potentiate rather than blunt psychedelic effects, so a dose intended to be sub-perceptual may not be. Mitigation: if unavoidable, treat any given microgram figure as functionally larger and monitor blood pressure, given the additive cardiovascular load.

  • CYP2D6 inhibitors (paroxetine, fluoxetine, bupropion, quinidine, terbinafine): Severity — caution. Inhibiting the principal clearance enzyme raises exposure from a fixed dose. Mitigation: reduce the nominal dose or space administration from the inhibitor; this is a common and easily missed interaction because several of these drugs are themselves antidepressants.

  • Ergot-derived and 5-HT2B-active medications (methysergide, ergotamine, pergolide, cabergoline, bromocriptine): Severity — absolute contraindication for chronic co-use. These are the exact agents implicated in drug-induced valve fibrosis, and combining them with a compound that engages the same receptor removes any safety margin. Mitigation: none other than avoidance.

  • Antihypertensives and other blood-pressure-lowering medication (amlodipine, lisinopril, losartan, metoprolol): Severity — monitor. The interaction is directional opposition rather than danger: transient pressure elevation on dosing days can partially offset therapy. Mitigation: measure blood pressure on dosing and non-dosing days before drawing conclusions about either.

  • Over-the-counter medications: Severity — caution. Dextromethorphan (in cough preparations) is serotonergic and adds to serotonin load; pseudoephedrine and phenylephrine (in decongestants) add to the blood-pressure effect; St John’s wort, though sold as a supplement, behaves as a serotonergic agent and a strong CYP3A4 inducer that will also lower exposure. Mitigation: separate decongestant use from dosing days and treat St John’s wort as an antidepressant for interaction purposes.

  • Supplement interactions with additive serotonergic effect: 5-hydroxytryptophan (5-HTP, a direct serotonin precursor), L-Tryptophan, S-adenosylmethionine (SAMe) and high-dose Rhodiola rosea extract all raise serotonergic tone and compound the same load. Severity — caution. Mitigation: avoid combining on dosing days; separate by at least 24 hours if used at all.

  • Supplements with additive cardiovascular or stimulant effect: Caffeine at high intake, yohimbine, synephrine and high-dose Panax ginseng add to the blood-pressure and arousal effects, and are the most likely contributors to dosing-day anxiety in practice. Severity — caution. Mitigation: reduce stimulant intake on dosing days rather than adjusting the microdose.

  • Supplements that alter clearance: Grapefruit juice, quercetin and berberine inhibit CYP3A4 and can raise exposure; St John’s wort induces it and lowers exposure. Severity — monitor. Mitigation: keep the surrounding supplement regimen constant across dosing days so that variability in effect is attributable to the intervention rather than to co-exposure.

  • Other interventions: Severity — caution. Full-dose psychedelic sessions produce cross-tolerance lasting several days, so a microdose taken close to a session will do little; ketamine therapy and repetitive transcranial magnetic stimulation both target overlapping plasticity pathways with no data on combination; alcohol adds cardiovascular and cognitive burden without pharmacological synergy. Mitigation: allow at least a week after a full-dose session before resuming, and keep alcohol off dosing days so that any effect is attributable to the intervention.

  • Populations who should avoid this intervention: Anyone with a personal or first-degree family history of bipolar I or II disorder, schizophrenia or other psychotic disorder. Anyone with known valvular heart disease of any grade, including trivial or mild regurgitation on echocardiography, or with pulmonary hypertension. Anyone with uncontrolled hypertension (persistently at or above 140/90 mmHg), unstable coronary disease, recent myocardial infarction (heart attack) within 90 days, or a history of stroke or transient ischaemic attack (a temporary interruption of blood flow to the brain, sometimes called a mini-stroke) within 12 months. Anyone with a seizure disorder, or with significant hepatic impairment at Child-Pugh Class B or C (a scoring system for liver function in which Class C indicates severe impairment), given that clearance depends on liver enzymes. Anyone pregnant, attempting conception or breastfeeding, since no reproductive safety data exist for LSD or any analogue. Anyone taking lithium or a monoamine oxidase inhibitor. Anyone in a safety-critical occupation where the documented reduction in cognitive control carries third-party consequences.

Risk Mitigation Strategies

  • Echocardiographic baseline before sustained use: An echocardiogram (an ultrasound scan of the heart) before starting, with repeat imaging at 12 months and every 12–24 months thereafter, is the only way to detect the valve fibrosis that is the principal theoretical long-term risk. This mirrors the surveillance schedule used for dopamine agonists with the same receptor profile, and it converts an unmonitorable risk into a detectable one. Any new or worsening regurgitation is a stop signal, not a monitoring finding.

  • Capped cumulative exposure with scheduled off-periods: Because the valve concern is driven by cumulative receptor activation rather than peak dose, running eight to twelve weeks on followed by four weeks off roughly halves lifetime exposure relative to continuous use, while preserving the acute effects that occur on dosing days anyway. Continuous multi-year dosing is the exposure pattern for which there is no safety data at all.

  • Volumetric dosing rather than blotter fractions: Dissolving a known quantity in a measured volume of distilled water or ethanol and dispensing by syringe gives dose accuracy of roughly ±10%, against ±50% or worse for cutting blotter squares, which are not loaded uniformly. This addresses both the dose-drift risk from chemical degradation and the risk of unintentionally crossing the 10 µg perceptual threshold.

  • Low starting dose at or below 5 µg equivalent with slow titration: A 5 µg dose produced no detectable subjective effect in controlled work and 10 µg is the established threshold for any psychotropic effect, so starting at the low end and increasing by 2–3 µg every two to three doses identifies the individual threshold without overshooting it. This directly mitigates treatment-emergent anxiety, which is dose-dependent and was the leading cause of trial withdrawal.

  • Morning-only dosing on a fixed schedule: Administering before 10:00 keeps the five-hour active window well clear of sleep onset and matches the protocols under which no dosing-day sleep disruption was observed. It also standardises the comparison between dosing and non-dosing days, which is the only way to detect a real effect against expectation.

  • Three- to four-day dosing interval, never daily: This spacing is what every controlled trial used and is designed to prevent the 5-HT2A receptor downregulation that produces tolerance at higher exposures. Shortening the interval increases cumulative receptor activation — the driver of the fibrosis concern — without evidence of added benefit.

  • Analytical testing of every batch, with reagent testing as a floor: Sending a sample to a drug-checking service that reports by mass spectrometry identifies the actual compound and detects the substitution of uncharacterised analogues such as 1cP-AL-LAD or 1cP-MIPLA. Reagent testing (Ehrlich’s reagent) confirms an indole compound but cannot distinguish which analogue is present, so it mitigates only the crudest substitution risk.

  • Cold, dark, dry storage with a six-month discard point: Refrigeration below 4 °C in an opaque, airtight container with desiccant limits the heat and moisture exposure that drives hydrolysis of prodrug to free LSD. Because storage-time drift has never been measured, discarding rather than using aged material is a precaution against a stable regimen silently changing dose.

  • Blood-pressure measurement on dosing and non-dosing days for the first month: Readings taken two hours post-dose and again on the following non-dosing day quantify the individual pressure response rather than assuming it matches the trial average. This mitigates the cumulative vascular risk that matters most over a longevity timeframe, and identifies the minority in whom the rise is not trivial.

  • Self-blinded trial period before committing: Preparing identical dosed and undosed capsules, randomising them and recording outcomes before unblinding is the only practical way to separate a real personal effect from expectation — the failure mode that the largest placebo-controlled dataset identified. Four to six weeks with roughly equal numbers of each is sufficient to detect an effect of the size reported in trials.

  • Medication and supplement screening at the outset and at any change: Checking specifically for lithium, monoamine oxidase inhibitors, ergot derivatives, dopamine agonists, and CYP2D6 inhibitors closes the three absolute contraindications and the main exposure-raising interaction. Re-screening matters because a new prescription can convert a stable regimen into a contraindicated one without any change in dosing.

Therapeutic Protocol

No clinical practitioner protocol exists for LSD analogues, because the compounds are not prescribable anywhere and no clinician can legally supervise their use. What follows is drawn from the dosing regimens used in controlled trials of low-dose LSD, from the published clinical trial protocols that are closest to real-world use, and from the two schedules that dominate the practice.

  • Dose range: Trials converge on 5–20 µg of LSD base, with 10 µg established as the threshold for any perceptible psychotropic effect and 20 µg producing both good and bad drug effects. The most clinically informed regimen — an open-label depression trial run at the University of Auckland — started at 8 µg and titrated between 6 and 20 µg twice weekly based on subjective perception and tolerability. For analogue blotter, the nominal microgram figure is stated as LSD equivalent, but conversion efficiency in humans is unmeasured, so a stated 10 µg is an approximation rather than a delivered dose.

  • The Fadiman schedule (one day on, two days off): The three-day cycle popularised by James Fadiman, whose survey work established the practice’s modern form, and the schedule used in the six-week home-administration trial and the sleep study. Doses fall on days 1, 4, 7 and so on. It is the better-validated of the two schedules.

  • The Stamets protocol (four days on, three days off): Popularised by mycologist Paul Stamets for psilocybin and adapted informally to lysergamides, this uses four consecutive dosing days followed by three off. It has never been tested in a controlled trial with LSD, and its consecutive-day structure conflicts with the tolerance rationale that motivates three-day spacing. It is presented here because it is widely used, not because it is supported.

  • The clinical-trial schedule (twice weekly, titrated): Used in both the Auckland open-label trial, which titrated between 6 and 20 µg, and its randomised successor, which widens the range to 4–20 µg, this delivers two doses per week with the dose itself adjusted according to perceptibility. It differs from both community schedules by titrating dose rather than fixing it, and it is the approach with formal ethics and safety oversight behind it.

  • Best time of day: Morning, before 10:00. Effects begin at about 1.1 hours and end at about 5.1 hours after a 10 µg dose, so morning administration confines the active window to the working day. Every controlled trial dosed in the morning, so evening dosing is entirely untested. The prodrug conversion step adds an unquantified delay of tens of minutes relative to LSD itself, arguing for earlier rather than later.

  • Half-life: The mean elimination half-life of LSD after low doses is 2.7 hours, with a range of 1.5–6.2 hours, and peak plasma levels at about 1.1 hours. This short half-life is why the practice is built around intermittent dosing rather than steady-state exposure, and why no accumulation occurs across a three-day cycle.

  • Single versus split dosing: Every controlled trial administered a single dose per dosing day, and no data support splitting. Splitting would extend the window of active drug and, with it, the daily period of reduced cognitive control, without raising peak effect — the opposite of what the acute-effect profile favours.

  • Administration route and formulation: Oral, either as blotter placed sublingually or as a volumetric solution. Volumetric dosing is preferred for accuracy. Food does not meaningfully alter absorption, but a consistent fed or fasted state reduces variability in onset.

  • Genetic polymorphisms affecting protocol: CYP2D6 status is the most relevant, since poor metabolisers reach higher exposure from the same nominal dose and may find 5 µg perceptible where others find 10 µg sub-threshold. COMT (catechol-O-methyltransferase, an enzyme that clears dopamine in the prefrontal cortex) genotype influences baseline cognitive-control capacity and may determine who is most affected by the documented decrement. Commercial pharmacogenetic panels report both.

  • Sex-based differences in dosing: No trial has established a sex-specific dose, because the two largest controlled datasets enrolled men only. Lower average body weight and documented sex differences in CYP2D6 and CYP3A4 activity both argue for women starting at the lower end of the range, and the first trial to enrol women exclusively is only now beginning.

  • Age-related considerations: Repeated dosing at 5, 10 and 20 µg every four days was well tolerated in adults averaging 62.9 years, which is the only age-specific dosing data available. Declining hepatic clearance and greater consequence from transient blood-pressure elevation both favour the lower half of the range and a four-day rather than three-day interval past age 60.

  • Baseline biomarkers influencing the protocol: Blood pressure and an echocardiogram are the two baseline measurements that define whether any dose is appropriate, and both precede dose selection. Baseline liver enzymes inform clearance expectations. For anyone on serotonergic medication, the expected blunting means the starting dose question is secondary to whether a meaningful response is achievable at all.

  • Pre-existing conditions influencing the protocol: Diagnosed depression is the condition with the most protocol-relevant data, and the titrated twice-weekly schedule was designed for it. Anxiety disorder argues for the slowest possible titration from the lowest dose. Chronic pain is the historical indication with the strongest low-dose signal, but the relevant threshold appears to sit at 20 µg — at the top of the microdose range and above where most schedules operate.

Discontinuation & Cycling

  • Lifelong versus time-limited use: Every controlled trial ran for six to eight weeks, and no study of any duration beyond that exists. The practice is most defensibly framed as time-limited — a defined trial period to establish whether a personal effect exists — rather than as an indefinite regimen, because the principal long-term risk accrues with cumulative exposure and has never been measured past two months in humans.

  • Withdrawal effects: None have been documented. Controlled trials reported no residual effects on mood or task performance at drug-free follow-up sessions three to four days after the final dose, and no withdrawal syndrome has been described for classic psychedelics at any dose. Classic psychedelics do not produce physical dependence, and their low reinforcement profile is one of the more consistent findings in the field.

  • Tapering: Not required. Because there is no dependence, no physiological adaptation requiring reversal, and no rebound described, stopping abruptly is the norm in trials and in practice. The exception is psychological: someone attributing substantial mood benefit to the practice may experience the loss of that expectation, which is a reason to stop during a stable rather than a stressful period.

  • Cycling for sustained efficacy: No evidence supports cycling to preserve efficacy, since tolerance has not been demonstrated at microdose exposures and trials showed no dose escalation over six weeks. Cycling is nonetheless reasonable for a different reason — limiting cumulative 5-HT2B receptor activation — which argues for eight to twelve weeks on followed by four weeks off, on a risk rather than efficacy rationale.

  • Reassessment at discontinuation: Because the effects that trials detect are confined to dosing days, an off-period is the natural point to compare functioning with and without the intervention. A four-week break with the same tracking used during dosing provides the within-person comparison that distinguishes a real carry-over effect from an acute one, and the sleep and mood measures used in trials are the most sensitive endpoints for this.

Sourcing and Quality

  • No legitimate supply chain exists: LSD analogues are not manufactured to any pharmaceutical standard, are not sold by any regulated pharmacy or compounding pharmacy, and no reputable brand can be named because no accountable manufacturer exists. Supply is exclusively through online research-chemical vendors operating in jurisdictions where a given analogue is not yet named in legislation. Every quality consideration below is a partial mitigation of that fundamental problem, not a solution to it.

  • Compound identity is the primary risk, not potency: National forensic laboratories repeatedly identify compounds in blotter that differ from what was advertised, including analogues modified at two positions simultaneously whose metabolism and pharmacology have never been reported. A vendor’s stated compound is an unverified claim until confirmed analytically.

  • Third-party analytical testing is the only meaningful verification: Drug-checking services that use mass spectrometry with nuclear magnetic resonance confirmation can identify the actual compound and detect substitution. Some vendors publish batch certificates of analysis; these are self-reported and unaudited, and are weaker evidence than independent testing. Colorimetric reagent tests confirm the presence of an indole compound but cannot distinguish between analogues.

  • Stated loading is nominal, not measured: Blotter is dosed by pipetting a solution onto sheets, and distribution across a sheet is not uniform. A square nominally carrying 100 µg may carry substantially more or less, which matters disproportionately when the intended dose is a tenth of a square. Volumetric preparation from a whole square dissolved in a measured volume corrects for within-square variation but not for sheet-level error.

  • Analogue choice affects stability: 1P-LSD is more stable than ALD-52 because its larger acyl group physically shields the bond from water, and later analogues with bulkier substituents are generally more resistant to premature hydrolysis. Where a choice exists, the more sterically hindered compound is the more predictable one over a storage period.

  • Storage conditions plausibly change the product: Cold, dark, dry and airtight storage limits the heat and moisture exposure that drives conversion of prodrug to free LSD, though no study has quantified how much a stored product drifts. Alcohol solvents demonstrably accelerate hydrolysis, which is relevant to anyone preparing volumetric solutions — distilled water with a small ethanol fraction is the common compromise, and such solutions are shorter-lived than the dry material.

  • Purity beyond identity is essentially unassessable: Synthesis impurities have been characterised for some analogues in forensic literature, but no consumer-accessible test detects them, and residual solvents, unreacted precursors and lysergamide by-products are not reported by drug-checking services. This is an irreducible unknown of the category.

Practical Considerations

  • Time to effect: Acute effects appear within the first dosing day — subjective changes begin at about 1.1 hours and the sleep effect appears the following night. Any cumulative effect, if it exists, is not detectable in trials: no questionnaire or cognitive measure changed between baseline and six weeks. A realistic assessment period is four to six weeks, long enough to accumulate roughly ten to fourteen dosing days for a within-person comparison.

  • Common pitfalls: Dose creep is the most frequent, as an absent effect prompts escalation past the 10 µg perceptual threshold into a dose that impairs a working day. Cutting blotter by eye rather than dosing volumetrically produces variation large enough to swamp any real effect. Failing to blind means the largest determinant of the reported outcome is expectation. Dosing too late in the day places active drug near sleep onset. Assuming that data on one analogue transfer to another ignores the documented differences in stability and predicted toxicity between them.

  • Regulatory status: LSD itself is Schedule I in the United States and equivalently controlled internationally, with no accepted medical use and no legal prescription route anywhere. The analogues occupy shifting ground: several are explicitly controlled in the United Kingdom and Germany, and those that remain unscheduled in the United States are still prosecutable under the Federal Analogue Act because they convert to a controlled substance. There is no off-label pathway, because there is no on-label use. Full-dose LSD is separately in late-stage clinical development for anxiety and depression, which may change the parent compound’s status but will not legitimise the analogues.

  • Cost and accessibility: Cost is not a barrier — analogue blotter typically works out to a few dollars per microdose, less than most supplement regimens. Accessibility is constrained by legality and supply volatility rather than price: vendors disappear, compounds are scheduled, and a regimen that is stable for a year can end abruptly. Analytical testing, where available, costs more per batch than the material itself. The cost gap against the competing options is large and cuts in one direction: a supervised full-dose psychedelic session runs to thousands of dollars in clinician time, whereas generic antidepressants and unpatentable gray-market blotter are both trivially cheap. Institutional payers — insurers and national health systems — therefore carry a systematic incentive to favour whichever model proves cheapest per durable outcome, and none carries any incentive to fund a definitive trial of an unpatentable practice that cannot be billed for; that asymmetry is a structural bias in guideline formation and research funding, running alongside the commercial sponsor bias identified elsewhere in this review.

  • Practical detectability: Standard workplace drug panels do not screen for LSD or its analogues, but specialised testing can detect LSD metabolites in urine for roughly one to three days and in hair for months. For anyone in a tested safety-critical role, detection remains possible on directed testing.

Interaction with Foundational Habits

  • Sleep: Direct and, on the available evidence, favourable. Device-measured sleep duration increased by roughly 24 minutes on nights following a dose, with no reduction on dosing days and no change in the proportion of time spent in each sleep stage — suggesting a genuine shift in sleep need rather than sedation. The proposed mechanism is serotonergic modulation of sleep-pressure regulation. Practically, this is the one effect with objective confirmation, which makes sleep tracking the single most useful measurement anyone can run alongside the practice; morning dosing is what keeps the five-hour active window clear of sleep onset.

  • Nutrition: Largely indirect, with two specific considerations. Serotonin synthesis depends on dietary tryptophan, and there is no evidence that microdosing depletes it, so no repletion is indicated; conversely, supplemental 5-hydroxytryptophan or L-Tryptophan adds serotonergic load, a compounding exposure on dosing days. Grapefruit and grapefruit juice inhibit CYP3A4 and can raise exposure, which makes it the one common food whose intake is best held constant rather than variable across dosing days. No specific dietary pattern potentiates or blunts the intervention, and neither fed nor fasted dosing is superior — consistency matters more than which is chosen.

  • Exercise: Direct but small, and bidirectional. Acute blood-pressure elevation on dosing days adds to the pressure response of hard training, which argues for separating high-intensity or heavy resistance sessions from the two-to-five-hour post-dose window; there is no evidence of blunted hypertrophy or impaired recovery. Against this, the documented reduction in cognitive control has implications for technique-dependent or risk-carrying training — heavy barbell work, climbing, cycling in traffic — where the faculty being impaired is precisely the one that prevents errors. Zone 2 cardiovascular work (steady, conversational-pace aerobic exercise) and mobility work are unaffected in practice.

  • Stress management: Direct and mixed. Acute effects on connectedness and mood are the most consistently reported subjective changes, and survey work associates microdosing with increased engagement in contemplative practice — which may be the mechanism by which reported benefits arise, rather than a pharmacological effect on stress physiology. Working against this, treatment-emergent anxiety is the leading adverse effect and the leading cause of trial dropout, and stimulant intake on dosing days appears to be a common contributor. No trial has measured cortisol or any other stress-axis marker after repeated microdosing, so the direction of any physiological effect on the stress response is unknown. Practically, dosing days are better paired with lower-demand schedules and existing meditation or breathwork practice than with high-pressure commitments.

Monitoring Protocol & Defining Success

Before starting, a baseline panel establishes both eligibility and the reference points against which any change is judged. Because the principal long-term concern is cardiac and the principal short-term concerns are vascular and psychiatric, baseline testing centres on the heart, blood pressure and mood rather than on a broad metabolic workup. An echocardiogram and a blood-pressure series are the two baseline measurements that can actually change the decision to proceed.

Ongoing monitoring runs on two cadences. Blood pressure and symptom tracking are daily for the first four weeks, then weekly. Blood work is repeated at 3 months and then every 6–12 months. Echocardiography is repeated at 12 months and then every 12–24 months for anyone continuing beyond a year, which is the surveillance interval used for other drugs acting at the same receptor.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Echocardiogram (valve morphology and regurgitation grade) No regurgitation beyond trivial; no leaflet thickening or restriction Detects the fibrotic valve change that is the main theoretical long-term risk An ultrasound scan of the heart. Baseline is mandatory before sustained use; repeat at 12 months, then every 12–24 months. Any new or progressing regurgitation is a stop signal. Mirrors surveillance used for dopamine agonists
Blood pressure (seated, home series) Below 120/80 mmHg on non-dosing days; rise under 10 mmHg systolic on dosing days Quantifies the individual vascular response rather than assuming the trial average Take two hours post-dose and again the following non-dosing day. Averaged over three readings, morning, before caffeine. mmHg = millimetres of mercury, the standard pressure unit
Resting heart rate 50–70 bpm, with under 5 bpm difference between dosing and non-dosing days Tracks the adrenergic component of the acute response and general cardiovascular load Best captured continuously by a wearable, which also supplies the sleep data. Conventional labs and clinics call 60–100 bpm normal, a considerably wider band than the functional target. bpm = beats per minute
hs-CRP Below 1.0 mg/L Tests whether the anti-inflammatory rationale for longevity use has any personal signal High-sensitivity C-reactive protein, a marker of low-grade systemic inflammation. Conventional labs report under 3.0 mg/L as normal. Invalid within two weeks of infection or intense training. Fasting not required
ALT and AST ALT below 25 U/L (men) or 20 U/L (women); AST below 25 U/L Confirms the liver, which performs clearance, is unaffected Alanine and aspartate aminotransferase, enzymes released when liver cells are stressed. Conventional upper limits near 40 U/L are considerably looser than functional targets. Fasting preferred; avoid after heavy exercise
Complete blood count Within reference range, with attention to platelets and white cell count Addresses the predicted haematological signal flagged for 1P-LSD and 1B-LSD in computational profiling The prediction is in silico only and has never been tested in a person; this is precautionary rather than evidence-driven. Pair with the liver panel on the same draw
ECG (12-lead), with QTc interval QTc below 440 ms (men) or 460 ms (women) Addresses the predicted cardiac ion-channel effect, strongest for 1V-LSD Electrocardiogram, a recording of the heart’s electrical activity; QTc is the corrected interval for ventricular repolarisation. hERG (the potassium channel whose blockade prolongs QTc) inhibition was predicted computationally, not measured. Baseline and annually
Fasting glucose and HbA1c Glucose 75–85 mg/dL; HbA1c 4.8–5.2% Establishes that a serotonergic intervention is not disturbing metabolic control Glycated haemoglobin, reflecting average glucose over roughly three months. Conventional cut-offs of 100 mg/dL and 5.7% are substantially looser. Requires 8–12 hours fasting
Thyroid panel (TSH, free T3, free T4) TSH 1.0–2.0 mIU/L; free T3 and free T4 in the upper half of reference Excludes thyroid dysfunction as a confounder for mood, sleep and energy changes Thyroid-stimulating hormone and the two circulating thyroid hormones. Conventional labs call anything from 0.4 to 4.5 mIU/L normal, a far wider band than the functional target. Draw in the morning; results shift with time of day and with biotin supplementation, which is stopped 72 hours before

Qualitative markers are as important as laboratory values here, because the endpoints the intervention plausibly affects are subjective and because the trials that found anything found it on daily questionnaires rather than in blood. In the trial protocols these are recorded on both dosing and non-dosing days, ideally under self-blinded conditions:

  • Sleep duration and quality: Total sleep time from a wearable on the night after each dose against non-dosing nights. This is the only endpoint with objective placebo-controlled support and the most likely place to see a real personal signal.

  • Mood, energy and irritability: Brief daily ratings on a fixed scale, since these were the specific dimensions that improved on dosing days in the largest home trial. Rating at a consistent time matters more than which scale is used.

  • Anxiety: Tracked separately from mood, because it is the leading adverse effect and the leading reason for stopping. A sustained rise across two or more consecutive dosing days is a signal to reduce the dose or stop.

  • Cognitive control in daily work: Errors of inattention, difficulty holding to an intention, and susceptibility to distraction on dosing days. Pooled evidence points to impairment here, so this is a check on the direction the practice is actually moving rather than on whether it is working.

  • Sense of connectedness and engagement: Reported improvements on dosing days in controlled work, and plausibly the mediator of downstream behavioural change.

  • Success definition: A meaningful result is a consistent, direction-specific difference between dosing and non-dosing days that survives a self-blinded comparison — not a general sense of improvement, which the placebo-controlled data show occurs equally without the drug. Absence of any blinded difference after four to six weeks, or any new echocardiographic finding at any point, is a reason to stop rather than to escalate.

Emerging Research

  • The first randomised trial of microdosing for depression: LSDDEP2 is a randomised, double-dummy, triple-blind, active-placebo-controlled trial of an eight-week LSD microdosing regimen in major depressive disorder, using a titratable 4–20 µg formulation self-administered at home twice weekly, with electroencephalography, blood biomarkers, and sleep and activity tracking alongside depression scores. It follows an open-label pilot in the same programme. The full protocol is published - Daldegan-Bueno et al., 2024. The trial is registered with the Australian New Zealand Clinical Trials Registry as ACTRN12624000128594, with 89 participants enrolled, and has no ClinicalTrials.gov NCT identifier. It is co-funded by MindBio Therapeutics Ltd., which is commercialising the formulation under test and therefore holds a direct financial interest in the outcome. Its active-placebo design is the direct answer to the expectancy critique, and it is the study most likely to settle whether microdosing produces a real clinical effect.

  • Microdosing in women, the first female-only trial: NCT07189299, “Microdosing LSD in Women With Premenstrual Disorders,” is a 150-participant study led from Basel, targeting change in premenstrual symptom burden as its primary endpoint. It is not yet recruiting. Because every large controlled microdosing dataset to date enrolled men exclusively, this is the first trial capable of establishing whether the sex-specific response and risk questions raised throughout this review have answers.

  • Head-to-head pharmacokinetics of an LSD analogue: NCT07309471, “Pharmacokinetics of Didehydro-LSD (DDH-LSD) Compared With LSD,” is a 24-participant Basel study, currently recruiting, comparing a distinct LSD analogue directly against LSD itself. It is the closest thing to a controlled human study of an analogue, and its methodology — direct pharmacokinetic comparison against the parent compound — is exactly what is missing for 1P-LSD, 1cP-LSD and the rest of the family.

  • Receptor occupancy mapping across the dose range: NCT05953038, “LSD Occupancy of the Serotonin 2A Receptor in the Human Brain,” is a 40-participant early-phase imaging study in Denmark, active and no longer recruiting, giving single doses of 25 to 200 µg of LSD equivalent freebase. Extrapolating the resulting occupancy-to-dose curve downward would let the field state what fraction of receptors a microdose actually engages — currently an assumption rather than a measurement, and the number on which both the efficacy and the 5-HT2B safety arguments depend.

  • Full-dose LSD in late-stage development: NCT06809595, “A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama),” enrols 245 participants and is active and no longer recruiting, one of several phase 3 programmes run by Definium Therapeutics US, Inc. This is full-dose rather than microdose LSD, but a regulatory approval would transform the parent compound’s legal and research status. The sponsor has a direct financial interest in favourable results, and this commercial programme is now the largest single funder of LSD clinical data.

  • Evidence that could strengthen the case — cardiac safety: Assessing the Potential Cardiovascular Risk of Microdosing the Psychedelic LSD in Mice - Effinger et al., 2025, found no ventricular or valvular remodelling after chronic low-dose LSD while positive controls produced the expected damage, and calculated that 5-HT2B activation from low-dose LSD is substantial but short-lived. This cuts in favour of the intervention, but the same group notes it does not resolve the multi-year human exposure question. The counterweight is the first human echocardiographic data, from LSD microdosing in major depressive disorder: results from an open-label trial - Daldegan-Bueno et al., 2026, which found no valvular change over eight weeks in 19 people — a reassuring but very short observation.

  • Evidence that could weaken the case — cognitive effects: The pooled finding of reduced cognitive control - Pinhas et al., 2026, is recent and rests on 14 heterogeneous studies. Replication in adequately powered, preregistered trials with standardised cognitive batteries would either confirm that the practice degrades the faculty it is taken to improve, or reveal the finding as an artefact of pooling incompatible tasks. This is the single result most capable of changing how a longevity-oriented reader weighs the intervention.

  • Non-hallucinogenic analogues as a competing direction: A non-hallucinogenic LSD analog with therapeutic potential for mood disorders - Lewis et al., 2023, and Molecular design of a therapeutic LSD analogue with reduced hallucinogenic potential - Tuck et al., 2025, describe engineered lysergamides that retain antidepressant-like activity while separating out the psychedelic effect. If this line succeeds, it would supersede microdosing’s central premise — that a small dose of a psychedelic is the way to get therapeutic effect without the experience — by delivering the same separation through molecular design rather than dose reduction. These programmes are commercially sponsored and their developers hold a financial interest in displacing the existing compounds.

  • What remains entirely unstudied: No registered trial anywhere tests 1P-LSD, 1cP-LSD, 1V-LSD, 1D-LSD or any other market analogue in humans. No study of any duration has measured inflammatory markers, biological-age markers, or cognitive trajectory after repeated microdosing. No trial has run longer than eight weeks. Until at least one of these gaps closes, every claim about LSD analogues for longevity is an extrapolation across two untested steps: from LSD to its prodrugs, and from weeks to years.

Conclusion

Microdosing LSD analogues means taking very small, repeated doses of compounds that the body converts into LSD. That conversion is the best-established fact in this area — the analogues are delivery vehicles rather than drugs in their own right — and it is also the reason the whole practice rests on borrowed evidence. Not one of these compounds has ever been tested in a person under controlled conditions.

What controlled work on low-dose LSD itself shows is modest and mostly confined to the day of dosing: longer sleep the following night, better-rated mood and energy while the drug is active, and a reassuring short-term safety record. What it does not show is any lasting change once dosing stops, and the pooled evidence points to a small reduction in the mental control needed to hold to an intention — the opposite of the practice’s central claim. In one large study, people improved just as much when they only believed they had taken something.

The main uncertainties are the heart, over years rather than weeks, and the product itself, which comes from unregulated sellers and is repeatedly found to contain compounds nobody has studied. Much of the research on all sides is funded by companies with a commercial stake — both the most reassuring safety data and the main warning about the heart. The honest position is that this is an inexpensive practice with a small, largely same-day effect, an untested long horizon, and a supply chain nobody stands behind.

Top - Benefits - Risks - Protocol